Twist Bioscience Corporation Selling, General and Administrative Expense
Twist Bioscience Corporation (TWST) reported Selling, General and Administrative Expense of $80.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-03
- Twist Bioscience Corporation selling, general and administrative expense for the quarter ending 2026-06-30 was $80.71M, a 27.36% increase year-over-year.
- Twist Bioscience Corporation selling, general and administrative expense for the quarter ending 2026-03-31 was $76.08M, a 19.50% increase year-over-year.
- Twist Bioscience Corporation selling, general and administrative expense for the quarter ending 2025-12-31 was $69.74M, a 24.15% increase year-over-year.
- Twist Bioscience Corporation selling, general and administrative expense for the quarter ending 2025-09-30 was $63.76M, a 19.97% increase year-over-year.
- Twist Bioscience Corporation selling, general and administrative expense for fiscal 2025 was $246.98M, a 13.09% increase from fiscal 2024.
- Twist Bioscience Corporation selling, general and administrative expense for fiscal 2024 was $218.40M, a 15.11% increase from fiscal 2023.
- Twist Bioscience Corporation selling, general and administrative expense for fiscal 2023 was $189.74M, a 10.90% decline from fiscal 2022.
- Twist Bioscience Corporation selling, general and administrative expense for fiscal 2022 was $212.95M, a 56.69% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $80.71M 10-Q · filed 2026-08-03 | $156.79M derived: sum of 2 quarters · filed 2026-08-03 | $226.54M 10-Q · filed 2026-08-03 | $290.29M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $76.08M 10-Q · filed 2026-05-04 | $145.83M 10-Q · filed 2026-05-04 | $209.58M derived: sum of 3 quarters · filed 2026-05-04 | $272.95M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $69.74M 10-Q/A · filed 2026-02-26 | $133.50M derived: sum of 2 quarters · filed 2026-02-26 | $196.87M derived: sum of 3 quarters · filed 2026-08-03 | $260.54M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-09-30 | $63.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $127.13M derived: sum of 2 quarters · filed 2026-08-03 | $190.80M derived: sum of 3 quarters · filed 2026-08-03 | $246.98M 10-K · filed 2025-11-17 |
| 2025-06-30 | $63.37M 10-Q · filed 2026-08-03 | $127.04M derived: sum of 2 quarters · filed 2026-08-03 | $183.22M 10-Q · filed 2026-08-03 | $236.36M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $63.67M 10-Q · filed 2026-05-04 | $119.85M 10-Q · filed 2026-05-04 | $172.99M derived: sum of 3 quarters · filed 2026-05-04 | $229.78M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $56.18M 10-Q/A · filed 2026-02-26 | $109.32M derived: sum of 2 quarters · filed 2026-02-26 | $166.11M derived: sum of 3 quarters · filed 2026-02-26 | $221.74M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-09-30 | $53.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $109.94M derived: sum of 2 quarters · filed 2025-11-17 | $165.56M derived: sum of 3 quarters · filed 2025-11-17 | $218.40M 10-K · filed 2025-11-17 |
| 2024-06-30 | $56.79M 10-Q · filed 2025-08-04 | $112.42M derived: sum of 2 quarters · filed 2025-08-04 | $165.26M 10-Q · filed 2025-08-04 | $212.65M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-03-31 | $55.62M 10-Q · filed 2025-05-05 | $108.46M 10-Q · filed 2025-05-05 | $155.85M derived: sum of 3 quarters · filed 2025-11-17 | $201.91M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-12-31 | $52.84M 10-Q · filed 2025-02-03 | $100.23M derived: sum of 2 quarters · filed 2025-11-17 | $146.29M derived: sum of 3 quarters · filed 2025-11-17 | $200.25M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-09-30 | $47.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $93.45M derived: sum of 2 quarters · filed 2025-11-17 | $147.41M derived: sum of 3 quarters · filed 2025-11-17 | $189.74M 10-K · filed 2025-11-17 |
| 2023-06-30 | $46.06M 10-Q · filed 2024-08-02 | $100.02M derived: sum of 2 quarters · filed 2024-08-02 | $142.35M 10-Q · filed 2024-08-02 | $196.50M derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-03-31 | $53.97M 10-Q · filed 2024-05-02 | $96.29M 10-Q · filed 2024-05-02 | $150.45M derived: sum of 3 quarters · filed 2024-11-18 | $204.14M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-12-31 | $42.32M 10-Q · filed 2024-02-02 | $96.48M derived: sum of 2 quarters · filed 2024-11-18 | $150.18M derived: sum of 3 quarters · filed 2024-11-18 | $204.17M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-09-30 | $54.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | $107.85M derived: sum of 2 quarters · filed 2024-11-18 | $161.85M derived: sum of 3 quarters · filed 2024-11-18 | $212.95M 10-K · filed 2024-11-18 |
| 2022-06-30 | $53.69M 10-Q · filed 2023-08-07 | $107.69M derived: sum of 2 quarters · filed 2023-08-07 | $158.79M 10-Q · filed 2023-08-07 | $197.03M derived: sum of 4 quarters · filed 2023-11-21 |
| 2022-03-31 | $54.00M 10-Q · filed 2023-05-08 | $105.10M 10-Q · filed 2023-05-08 | $143.34M derived: sum of 3 quarters · filed 2023-11-21 | $177.82M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-12-31 | $51.10M 10-Q · filed 2023-02-07 | $89.34M derived: sum of 2 quarters · filed 2023-11-21 | $123.82M derived: sum of 3 quarters · filed 2023-11-21 | $158.21M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-09-30 | $38.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | $72.72M derived: sum of 2 quarters · filed 2023-11-21 | $107.11M derived: sum of 3 quarters · filed 2023-11-21 | $135.90M 10-K · filed 2023-11-21 |
| 2021-06-30 | $34.48M 10-Q · filed 2022-08-08 | $68.87M derived: sum of 2 quarters · filed 2022-08-08 | $97.66M 10-Q · filed 2022-08-08 | $124.84M derived: sum of 4 quarters · filed 2023-06-05 |
| 2021-03-31 | $34.39M 10-Q · filed 2022-05-06 | $63.18M 10-Q · filed 2022-05-06 | $90.37M derived: sum of 3 quarters · filed 2023-06-05 | $112.85M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-12-31 | $28.79M 10-Q · filed 2022-02-09 | $55.98M derived: sum of 2 quarters · filed 2023-06-05 | $78.46M derived: sum of 3 quarters · filed 2023-06-05 | $105.65M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-09-30 | $27.18M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | $49.67M derived: sum of 2 quarters · filed 2023-06-05 | $76.86M derived: sum of 3 quarters · filed 2023-06-05 | $103.27M 10-K/A · filed 2023-06-05 |
| 2020-06-30 | $22.49M 10-Q · filed 2021-08-09 | $49.68M derived: sum of 2 quarters · filed 2021-08-09 | $76.08M 10-Q · filed 2021-08-09 | $100.50M derived: sum of 4 quarters · filed 2021-11-23 |
| 2020-03-31 | $27.19M 10-Q · filed 2021-05-07 | $53.59M 10-Q · filed 2021-05-07 | $78.02M derived: sum of 3 quarters · filed 2021-11-23 | $99.34M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-12-31 | $26.41M 10-Q · filed 2021-02-09 | $50.83M derived: sum of 2 quarters · filed 2021-11-23 | $72.15M derived: sum of 3 quarters · filed 2021-11-23 | $91.27M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-09-30 | $24.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-23 | $45.74M derived: sum of 2 quarters · filed 2021-11-23 | $64.87M derived: sum of 3 quarters · filed 2021-11-23 | $80.13M 10-K · filed 2021-11-23 |
| 2019-06-30 | $21.32M 10-Q · filed 2020-08-12 | $40.44M derived: sum of 2 quarters · filed 2020-08-12 | $55.70M 10-Q · filed 2020-08-12 | $68.66M derived: sum of 4 quarters · filed 2020-11-27 |
| 2019-03-31 | $19.12M 10-Q · filed 2020-05-13 | $34.38M 10-Q · filed 2020-05-13 | $47.34M derived: sum of 3 quarters · filed 2020-11-27 | $58.59M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-12-31 | $15.26M 10-Q · filed 2020-02-10 | $28.21M derived: sum of 2 quarters · filed 2020-11-27 | $39.47M derived: sum of 3 quarters · filed 2020-11-27 | $49.45M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-09-30 | $12.95M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-27 | $24.21M derived: sum of 2 quarters · filed 2020-11-27 | $34.19M derived: sum of 3 quarters · filed 2020-11-27 | $43.45M 10-K · filed 2020-11-27 |
| 2018-06-30 | $11.26M 10-Q · filed 2019-08-09 | $21.23M derived: sum of 2 quarters · filed 2019-08-09 | $30.50M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $9.98M 10-Q · filed 2019-05-02 | $19.24M 10-Q · filed 2019-05-02 | ||
| 2017-12-31 | $9.26M 10-Q · filed 2019-02-11 | |||
| 2017-09-30 | $26.06M 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |